Switching atypical antipsychotics: A review

Acta Neuropsychiatrica

Volumn 16, Issue 6, 2004, Pages 301-313

  Chue, Pierre ^a,e   Stip, Emmanuel ^b   Remington, Gary ^c   Kopala, Lili ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e NONE   (Canada)

Author keywords

Amisulpride; Atypical antipsychotics; Clozapine; Olanzapine; Quetiapine; Ripiprazole; Risperidone; Schizophrenia; Switching; Ziprasidone

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGRANULOCYTOSIS; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NEUTROPENIA; PATIENT EDUCATION; PATIENT SELECTION; PSYCHOSIS; REBOUND; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN; WITHDRAWAL SYNDROME;

EID: 22344435670     PISSN: 09242708     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0924-2708.2004.00098.x     Document Type: Review

References (101)

1. NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. National Collaborating Centre for Mental Health (NCCMH), 25th March 2003.
2. VOLAVKA J. Are medication-free periods necessary for phase 3 trials of new antipsychotic drugs? Arch Gen Psychiatry 1998;55:280-1, 283.
3. WILLIAMS CL, JOHNSTONE BM, KESTERSON JG, JAVOR KA, SCHMETZER AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 1999;37:81-86.
4. KINON BJ, BASSON BR, GILMORE JA, MALCOLM S, STAUFFER VL. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 2000;61:833-840.
5. VORUGANTI L, CORTESE L, OWYEMI L et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophrenia Res 2002;57:201-208.
6. AMERY W, MARDER SR. Safety and switching issues of novel antipsychotics. Int J Psych Clin Practice 1998;2:S43-S49.
7. KINGSBURY SJ, SIMPSON GM. Principles for starting, stopping, or switching medications. Psychiatric Services 2002;53:1139-1140.
8. GANGULI R. Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm 2002;59:S22-S26.
9. COOK PE, GOLDBERG JO, VAN LIESHOUT RJ. Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Can J Psychiatry 2002;47:870-874.
10. WEIDEN PJ, AQUILA R, DALHEIM L, STANDARD JM. Switching antipsychotic medications. J Clin Psychiatry 1997;58:63-72.
11. MASAND PS, BERRY SL. Switching antipsychotic therapies. Ann Pharmacotherapy 2000;34:200-207.
12. TAYLOR D. Switching from typical to atypical antipsychotics. CNS Drugs 1997;8:285-292.
13. PEUSKENS J. Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol 2000;15:S15-S19.
14. BURNS T, CHABANNES JP, DEMYTTENAERE K. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin 2002;18:201-208.
15. RAFAL S, TSUANG MT, CARPENTER WT. A dilemma born of progress: switching from clozapine to a newer antipsychotic. Am J Psychiatry 1999;156:1086-1090.
16. BOGAN AM, SHELLHORN E, BROWN ES, MCDANALD C, SUPPES T. Switching outpatients between atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:351-355.
17. BEZCHLIBNYK-BUTLER KZ, JEFFRIES JJ, eds. Clinical Handbook of Psychotropic Drugs, 13th edn. Toronto, Canada: Hogrefe & Huber, 2003.
18. MELTZER HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992;160:46-53.
19. CANADIAN PHARMACISTS ASSOCIATION. CLOZARIL®. In: Compendium of Pharmaceuticals and Specialities. Toronto, Canada: Webcom Limited, 2003.
20. MELTZER HY, LEE MA, RANJAN R, MASON EA, COLA PA. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacol 1996;124:176-187.
21. CONLEY RR. Optimizing treatment with clozapine. J Clin Psychiatry 1998;59:44-48.
22. ARAVAGIRI M, MARDER SR, VAN PUTTEN T, MIDHA KK. Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. J Pharmaceut Sci 1993;82:447-449.
23. COATES J. Urinary detection of olanzapine - an aid to compliance. Br J Psychiatry 1999;175:591-592.
24. GREEN A. Predictors of response to clozapine. J Clin Psychiatry 1996;14:25-26.
25. ATKIN K, KENDALL F, GOULD D, FREEMAN H, LIBERMAN J, O'SULLIVAN D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996;169:483-488.
26. PRIOR T, BAKER G. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003;28:99-112.
27. BALDESSARINI R, GARDNER D, GARVER D. Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry 1996;52:1071-1072.
28. BOBBA R, CARR A. Severe extrapyramidal side effects when discontinuing clozapine and starting haloperidol. Can J Psychiatry 1997;42:530.
29. FRIEDMAN JH, GOLDSTEIN S, JACQUES C. Substituting clozapine for olanzapine in psychiatrically Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol 1998;21:285-288.
30. FERNANDEZ HH, LANNON MC, FRIEDMAN JH, ABBOTT BP. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15:579-581.
31. SHORE D. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 1995;21:333-338.
32. LEE JW, ROBERTSON S. Clozapine withdrawal catatonia and neuroleptic malignant syndrome: a case report. Ann Clin Psychiatry 1997;9:165-169.
33. LLORCA PM, PENAULT F, LANCON C, DUFUMIER E, VAIVA G. The concept of supersensitivity psychosis. The particular case of clozapine. Encephale 1999;25:638-644.
34. SZAFRANSKI T, GMURKOWSKI K. Clozapine withdrawal. A Review. Psychiatr Pol 1999;33:51-67.
35. GUPTA S, DANIEL DG. Cautions in the clozapine-torisperidone switch. Ann Clin Psychiatry 1995;7:149.
36. DELASSUS-GUENAULT N, JEGOUZO A, ODOU P et al. Clozapine-olanzapine: a potentially dangerous switch. A report of two cases. J Clin Pharm Ther 1999;24: 191-195.
37. ONOFRJ M, THOMAS A, BONANNI L, IACONO D, GAMBI F. Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine. Neurol Sci 2000;21:209-215.
38. DE LEON J, STANILLA JK, WHITE AO, SIMPSON GM. Anticholinergics to treat clozapine withdrawal. J Clin Psychiatry 1994;55:119-120.
39. KOREEN AR, LIEBERMAN JA, KRONIG M, COOPER TB. Cross-tapering clozapine and risperidone. Am J Psychiatry 1995;152:1690.
40. BENEDETTI F, CAVALLARO R, SMERALDI E. Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet 1999;354:567.
41. DIAZ P, HOGAN TP. Granulocytopenia with clozapine and quetiapine. Am J Psychiatry 2001;158:651.
42. GODLESKI LS, SERNYAK MJ. Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 1996;153:735-736.
43. BACHER NM, KAUP BA. Combining risperidone with standard neuroleptics for refractory schizophrenic patients. Am J Psychiatry 1996;153:137.
44. RADFORD J, BROWN T, BORISON R. Unexpected dystonia while changing from clozapine to risperidone. J Clin Psychopharmacol 1995;15:225-226.
45. EKBLOM B, ERIKSSON K, LINDSTROM LH. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology 1984;83:293-294.
46. DICKSON R, WILLIAMS R, DALBY JT. Dystonic reactions and relapse with clozapine discontinuation and risperidone initiation. Can J Psychiatry 1994;39:184.
47. BORISON RL, CONSENSUS STUDY GROUP ON RISPERIDONE DOSING. Changing antipsychotic medication; guidelines on the transition to treatment with risperidone. Clin Therapeutics 1996;18:592-607.
48. STILL DJ, DORSON PG, CRISMON ML, POUSSON C. Effects of switching inpatients with treatment resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47:1382-1384.
49. KOPALA LC. Clinical experience in developing treatment regimens with the novel antipsychotic risperidone. Int Clin Psychopharmacol 1997;12:S11-S18.
50. ZIMBROFF DL. Switching patients from clozapine to risperidone therapy. Am J Psychiatry 1995;152:1102.
51. HORNE RL, MILLER F. Outcome in patients switched from clozapine to risperidone. Poster NR447. Presented at 148th Ann Meet Am Psychiatric Assoc, May 20-25 1995, Miami, USA.
52. LANE HY, CHIU WC, CHOU JC, WU ST, SU MH, CHANG WH. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000;61:209-214.
53. FEIFEL D, MOUTIER CY, PERRY W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry 2000;61:909-911.
54. MAURI MC, LAINI V, BOSCATI L et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 2001;16:57-63.
55. WIRSHING WC, MARDER SR. Efficacy and dosing issues of novel antipsychotics. Int J Psychiatry Clin Practice 1998;2:S35-S38.
56. CANADIAN PHARMACISTS ASSOCIATION. RISPERDAL®. In: Compendium of Pharmaceuticals and Specialities. Toronto, Canada: Webcom Limited, 2003.
57. WILLIAMS RW. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 2001;62:282-289.
58. DESAI NM, HUQ Z, MARTIN SD, MCDONALD G, SCHIZOPHRENIA TREATMENT AND ASSESSMENT GROUP. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. Advan Ther 1999;16:78-88.
59. BENNIE EH. High-dose antipsychotic medication. Br J Psychiatry 1994;165:553.
60. KIROV GK, MURRAY RM, SETH RV, FEENEY S. Observations on switching patients with schizophrenia to risperidone treatment. Acta Psychiatr Scand 1997;95:439-443.
61. SCORDO MG, SPINA E, FACCIOLA G, AVENOSO A, JOHANSSON I, DAHL M-L. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 1999;147: 300-305.
62. DARBY JK, PASTA DJ, ELFAND L, DABIRI L, CLARK L, HERBERT J. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical setting. J Clin Psychopharmacol 1997;17:478-484.
63. 2 activity in plasma. Presented at XXII CNIP Congress, 9-13 July 2000, Brussels, Belgium.
64. YOSHIMURA R, NAKAMURA J, UEDA N, TERAO T. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9- hydroxyrisperidone, pMHPG levels, and clinical improvement. Int Clin Psychopharmacol 2000;15:175-180.
65. SPINA E, AVENOSO A, FACCIOLA G et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Therapeutic Drug Monitoring 2000;22:481-485.
66. FRACKIEWICZ EJ, HERRERA JM, SRAMEK JJ, COLLAZO Y, LAWSON WB. Risperidone in the treatment of Hispanic inpatients with schizophrenia: a pilot study. Psychiatry 2002;65:371-374.
67. GARDNER DM, BALDESSARINI RJ, BENZO J, ZARATE CA Jr, TOHEN M. Switching between clozapine and risperidone treatment. Can J Psychiatry 1997;42:430-431.
68. MOK H, YATHAM LN. Response to clozapine as a predictor of risperidone response in schizophrenia. Am J Psychiatry 1994;151:1393-1394.
69. CUTLER AJ, GOLDSTEIN JM, TUMAS JA. Dosing and switching strategies for quetiapine fumarate. Clin Therapeutics 2002;24:209-222.
70. GOLDSTEIN JM. Safety and tolerability of switching from conventional antipsychotic therapy to seroquel (quetiapine fumarate) followed by abrupt withdrawal from seroquel. Presented at 151st Ann Meet American Psychiatric Association, 30 May-4 June 1998, Toronto, Canada.
71. DEVANE CL, NEMEROFF CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001;40:509-522.
72. LEE CT, CONDE BJ, MAZLAN M et al. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry 2002;63:569-576.
73. LABELLE A, BOURGET D, BOULAY LJ, ELLIS J, TESSIER P. Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study. J Clin Psychopharmacol 2002;22:545-553.
74. LITTRELL KH, PEABODY C, JOHNSON C et al. Patients switched from depot antipsychotics to risperidone or olanzapine: an open-label randomized trial. Poster NR551. Presented at 152nd Ann Meet Am Psych Assocn, May 15-19 1999, Washington, DC.
75. GODLESKI LS, GOLDSMITH J, VIEWEG WV, ZETTWOCH NC, STIKOVAC DM, LEWIS SJ. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. J Clin Psychiatry 2003;62:119-122.
76. HENDERSON DC, NASRALLAH RA, GOFF DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 1998;59:585-588.
77. LITTRELL KH, JOHNSON CG, HILLIGOSS NM, PEABODY CD, LITTRELL SH. Switching clozapine responders to olanzapine. J Clin Psychiatry 2000;61:912-915.
78. TOLLEFSON GD, DELLVA MA, MATTLER CA, KANE JM, WIRSHING DA, KINON BJ. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. J Clin Psychopharmacol 1999;19:435-443.
79. CANADIAN PHARMACISTS ASSOCIATION. ZYPREXA®. In: Compendium of Pharmaceuticals and Specialities. Toronto, Canada: Webcom Limited, 2003.
80. WEIDEN PJ, SIMPSON GM, POTKIN SG, O'SULLIVAN RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003;64:580-588.
81. KINGSBURY SJ, FAYEK M, TRUFASIU D, ZADA J, SIMPSON GM. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001;62:347-349.
82. BEEDHAM C, MICELI JJ, OBACH RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 2003;23:229-232.
83. CASEY DE, CARSON WH, SAHA AR, LIEBESKIND A, ALI MW, JODY D, INGENITO GG. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacol (Berl) 2003;166:391-399.
84. BOWLES TM, LEVIN GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 2003;37:687-694.
85. PEUSKENS J. Switching to amisulpride. Curr Med Res Opin 2002;18:S23-S28.
86. LECRUBIER Y, AZORIN M, BOTTAI T et al. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuro-psychobiology 2001;44:41-46.
87. YAGDIRAN O, HAASEN C, NIKA E, KRAUSZ M, NABER D. Switching to amisulpride due to hepatic complications. Eur Psychiatry 2002;17:170-171.
88. JATZKO A, RIES S, SCHREINER A, BRAUS DF. Acute tongue and pharyngeal spasms during changeover from clozapine to amisulpride. A case example. Nervenarzt 2000;71:919-922.
89. LAMBERT T. Practical issues in switching to novel antipsychotics. Presented at the XXII CINP Congress, 9th-13th July 2000, Brussels, Belgium.
90. NAYUDU SK, SCHEFTNER WA. Case report of withdrawal syndrome after olanzapine discontinuation. J Clin Psychopharmacol 2000;20:489-490.
91. ANAND VS, DEWAN MJ. Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry 1996;8:179-182.
92. GILBERT PL, HARRIS MJ, MCADAMS LA, JESTE DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52:173-188.
93. VERGHESE C, DELEON J, NAIR C, SIMPSON G. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 1996;39: 135-138.
94. JESTE DV, ROCKWELL E, HARRIS MJ, LOHR JB, LACRO J. Conventional versus newer antipsychotics in elderly patients. Am J Geriatric Psychiatry 1991;7:70-76.
95. BARAK Y, SHAMIR E, WEIZMAN R. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective comparative study. J Clin Psychopharmacol 2002;22:115-120.
96. MALLA AK, NORMAN RM, KOTTEDA V, ZIRUL S. Switching from therapy with typical antipsychotic agents to risperidone: long term impact on patient outcome. Clin Ther 1999;21:806-817.
97. CONLON L, FAHY TJO, TOOLE R, GILLIGAN J, PRESCOTT P. Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow up of patients on depot medication. Eur Psychiatry 2002;17:459-465.
98. FLEISCHHACKER WW, EERDEKENS M, KARCHER K et al. Treatment of schizophrenia with long-acting risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-1257.
99. JANN MW. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol Bull 2002;36:22-41.
100. WEIDEN PJ, AQUILA R, EMANUEL M, ZYGMUNT A. Long-term considerations after switching antipsychotics. J Clin Psychiatry 1998;59:36-49.
101. ALTAMURA AC, SASSELLA F, SANTINI A, MONTRESOR C, FUMAGALLI S, MUNDO E. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003;63:493-512.